NCT07286682

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants

A Phase 1, Randomized, Placebo-Controlled Single Ascending Dose Participant- and Investigator-Blind Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending doses of UCB5285 in healthy study participants, including healthy Japanese study participants

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	UCB5285	Participants will receive UCB5285 as prespecified in each cohort.
OTHER	Placebo	Participants will receive matching placebo as prespecified in each cohort.

Timeline

• Start date: 2025-12-08
• Primary completion: 2026-12-13
• Completion: 2026-12-13
• First posted: 2025-12-16
• Last updated: 2025-12-23

Locations

1 site across 1 country: United Kingdom